Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus
- PMID: 27803306
- DOI: 10.1093/rheumatology/kew377
Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus
Abstract
Objectives: To identify predictors of organ damage and specifically the relationship between prolonged disease remission or low disease activity and damage accrual in a longitudinal cohort of SLE patients.
Methods: Data were prospectively assessed including the occurrence of minor/major flares. Once a year remission and Lupus Low Disease Activity State (LLDAS) were determined retrospectively. A prediction model for damage accrual during follow-up was constructed with backward logistic regression analyses. Secondly, odds ratios (ORs) for damage accrual (SLICC damage index increase of ⩾ 1 during follow-up) were calculated for patients with or without prolonged remission during 5 years, and with or without LLDAS in ⩾ 50% of observations.
Results: Data from 183 patients with a median follow-up duration of 5.0 years were analysed. The most significant predictors for damage accrual were: occurrence of ⩾ 1 major flare, mean daily prednisone dose during follow-up and nephrological manifestations at baseline. Prolonged remission was present in 32.5% (38/117) and LLDAS in ⩾ 50% of observations in 64.5% (118/183) of patients. Both the presence of prolonged remission during 5 years and LLDAS in ⩾ 50% of observations were associated with a reduced risk of damage accrual (OR = 0.20, 95% CI: 0.07, 0.53, P = 0.001 and OR = 0.52, 95% CI: 0.28, 0.99, P = 0.046, respectively).
Conclusion: This cohort study shows that prolonged remission and LLDAS were associated with an improved outcome, as determined by yearly assessments. In order to improve the outcome in SLE patients, future studies should investigate whether these targets can be reached actively with therapeutic strategies.
Keywords: cohort study; damage accrual; flare; glucocorticoids; low disease activity; lupus low disease activity state; lupus nephritis; remission; systemic lupus erythematosus.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Similar articles
-
Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus.Rheumatology (Oxford). 2014 Aug;53(8):1470-6. doi: 10.1093/rheumatology/keu148. Epub 2014 Mar 27. Rheumatology (Oxford). 2014. PMID: 24681836
-
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.Arthritis Rheumatol. 2018 Nov;70(11):1790-1795. doi: 10.1002/art.40571. Arthritis Rheumatol. 2018. PMID: 29806142 Free PMC article.
-
Association of lupus low disease activity state and remission with reduced organ damage and flare in systemic lupus erythematosus patients with high disease activity: a multi-national, longitudinal cohort study.Rheumatology (Oxford). 2025 May 1;64(5):2741-2748. doi: 10.1093/rheumatology/keae631. Rheumatology (Oxford). 2025. PMID: 39656834 Free PMC article.
-
Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus.Lupus. 2020 Sep;29(10):1155-1167. doi: 10.1177/0961203320930099. Epub 2020 Jun 15. Lupus. 2020. PMID: 32539657 Review.
-
Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual.Rheumatology (Oxford). 2021 Dec 1;60(12):5517-5526. doi: 10.1093/rheumatology/keab149. Rheumatology (Oxford). 2021. PMID: 33576768
Cited by
-
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis.Lupus Sci Med. 2022 Jan;9(1):e000603. doi: 10.1136/lupus-2021-000603. Lupus Sci Med. 2022. PMID: 34996857 Free PMC article.
-
The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus.Arthritis Res Ther. 2021 Jan 16;23(1):29. doi: 10.1186/s13075-021-02414-0. Arthritis Res Ther. 2021. PMID: 33451338 Free PMC article.
-
Global research trends in precision-targeted therapies for systemic lupus erythematosus (2003-2023): A bibliographic study.Heliyon. 2024 Jun 20;10(13):e33350. doi: 10.1016/j.heliyon.2024.e33350. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39050478 Free PMC article.
-
Childhood-Onset Systemic Lupus Erythematosus (cSLE): An International Perspective.Curr Allergy Asthma Rep. 2024 Oct;24(10):559-569. doi: 10.1007/s11882-024-01169-3. Epub 2024 Aug 15. Curr Allergy Asthma Rep. 2024. PMID: 39145903 Free PMC article. Review.
-
Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.Arthritis Res Ther. 2017 Nov 10;19(1):247. doi: 10.1186/s13075-017-1451-5. Arthritis Res Ther. 2017. PMID: 29126432 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical